ArticleMicrobial cell factories2025
Enhancing Bacillus cereus antibacterial ability through improved cofactor supply.
Article in Microbial cell factories, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Bacillus cereus 0-9 is a biocontrol microorganism that antagonizes Gram-positive bacteria and pathogenic fungi, such as Staphylococcus aureus and Gaeumannomyces graminis, through the secretion of antimicrobial peptides. However, its low antibacterial activity limits its biocontrol application. In this study, a significant enhancement in antibacterial activity against S. aureus was achieved by overexpressing glucose dehydrogenase from Bacillus subtilis (BsGDH) in B. cereus 0-9, expanding the activity from 6.98 to 11.59 U/mL, representing a 66% improvement. To further improve its biocontrol capability, we aimed to improve the catalytic efficiency of BsGDH by screening 11 low-conserved residues in the protein's second-shell via conservation analysis and molecular docking. Following three rounds of saturation mutagenesis, the specific enzyme activity and K
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.